Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Decreases By 31.9%

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 5,220,000 shares, a decrease of 31.9% from the October 31st total of 7,670,000 shares. Based on an average daily trading volume, of 37,050,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.8% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Friday. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Price Performance

Tonix Pharmaceuticals stock traded up $0.00 during mid-day trading on Friday, reaching $0.19. The company had a trading volume of 28,999,211 shares, compared to its average volume of 14,063,675. The business has a fifty day simple moving average of $0.16 and a 200 day simple moving average of $1.05. The company has a market cap of $35.45 million, a P/E ratio of 0.00 and a beta of 2.06. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.